Wilson Sonsini tops Life Sciences Law Firm Index for 2nd straight year
The Life Sciences Law Firm Index identifies the most active and relevant firms for life science companies.
Finding a way through a tight deal space
Leaders of WilmerHale’s life sciences practice share trends they see regarding acquisitions and initial public offerings.
presented by
5 Major Trends Emerging in Healthcare Benefits in 2025
Employees who enjoy their benefits are more inclined to stay with their company. A 2025 Marsh McLennan Agency report said 73% of employees would remain if plan options were better.
Navigating the Life Science M&A Savannah
Still recovering from a market correction two years ago, and with a scarcity of attractive targets and ongoing macroeconomic uncertainty, the life sciences dealmaking space is in a state of flux.
Collaboration at Fenwick & West Steers Firm through complex deals
After a relatively slow 2016 for life sciences deals...
Newly united Arnold & Porter Kaye Scholer surveys changed life sciences deal environment
Last year proved a slow one for dealmaking in the life sciences space. But that didn’t stop two of the major legal players in it from consummating one themselves: In November, Arnold & Porter and Kaye Scholer agreed to merge, bringing together two formidable healthcare practices.
Aggregate Spend Goes Global
This independent editorial series on healthcare and the law is sponsored by Lake Whillans, a distressed venture capital and litigation finance firm that helps companies facing litigation or arbitration. As states began to jump onto the pharmaceutical regulation bandwagon around the turn of the century, Porzio Bromberg & Newman brought John Ohoro on to help clients sift […]
presented by
The Top Surgical Instruments Needed for Extractions
Discover what tools are essential for efficient, safe surgical extractions in today’s health care landscape, from elevators to forceps and beyond.
Friends and Family (Offices) Step in to Funding Drought
Not too long ago, it didn’t take much for someone with an idea for a new medical device to rake in the early-stage funding. Investors have been a bit more discerning over the past decade, to say the least, and by and large they remain so, according to K&L Gates’ Michael Hedge, who’s been around long enough to […]
M&A: The Last Refuge for Biotechs Seeking Funding
These are tough times in the biotech and pharmaceutical industries: Funding is drying up, investors are fleeing the space, the IPO door is pretty firmly shut, valuations are dropping, activists are lurking and the headlines are anything but kind. But when the going gets tough, the tough consider strategic alternatives. Stuart Falber and Belinda Juran, […]